GlassScriptPhysician profile
Suresh Anne
NPI 1336101443
$14,545.23
in general payments reported to CMS, 2019-2025
42 companies · $3,096 in 2025
The $3,096 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $1,100 · 2021: $1,117 · 2022: $2,623 · 2023: $2,386 · 2024: $2,552 · 2025: $3,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,709 · Education: $283 · Consulting Fee: $41.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,709.07 |
| Education | $282.99 |
| Consulting Fee | $41.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,658.19 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,913.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,470.38 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $1,316.75 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $1,028.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $933.25 | 2019-2025 | |
| Amgen INC. | $746.31 | 2021-2025 | Tezspire, Actimmune |
| Pfizer INC. | $719.70 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $444.43 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $281.14 | 2019-2025 | Ruconest |
| Abbvie INC. | $243.36 | 2021-2023 | Rinvoq |
| Optinose US, INC. | $234.10 | 2019-2024 | |
| Genentech USA, INC. | $230.01 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $223.44 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $205.83 | 2020-2024 |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Anne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.